Comparing the current results to its competitors, Transcode Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.15 %, recorded in the same quarter.
October 10, 2024
Unlocking the Secrets of MicroRNA: TransCode Therapeutics Journey Toward Combatting Metastatic Cancer In the ever-evolving world of biotech innovation, TransCode Therapeutics is making bold strides with its groundbreaking microRNA-targeted technology. Their flagship candidate, TTX-MC138, is shining a promising light on the treatment of metastatic cancer. At the core of this pioneering work are recent milestones and revelations that not only highlight the potential of TTX-MC138 but also mark significant steps forward for TransCode Therapeutics as a rising star in the biopharmaceutical field. 1. Completion of Initial Dosing in Phase 1 Clinical Trial TransCode Therapeutics recently announced the successful dos...
May 29, 2024
The field of oncology has seen remarkable advancements in recent years, particularly with the emergence of RNA therapeutics. Among the notable contributors in this area is TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an innovative RNA oncology company committed to revolutionizing cancer treatment using RNA-based therapeutic candidates. In a recent announcement, TransCode Therapeutics reported encouraging results from a first-in-human clinical study involving their groundbreaking lead candidate, TTX-MC138. Additionally, the company is set to present Phase 0 data during the prestigious San Antonio Breast Cancer Symposium, which is scheduled to be held from December 5-9, 2023.Unveiling Positive Data from First-...
Publicly Traded Peers of Transcode Therapeutics Inc
Structure Therapeutics Inc Share Performance
-6.13%
This Quarter
Structure Therapeutics Inc
Profile
Structure Therapeutics Inc is a biotechnology company that utilizes a structure-based approach to develop innovative therapeutics. They focus on identifying and targeting unique protein structures to create novel drugs for various diseases.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Sources:
Transcode Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Transcode Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
